Immunogenicity of Heterologous Versus Homologous Prime Boost Schedule With mRNA and Inactivated COVID-19 Vaccines

NCT05668065 PHASE3 COMPLETED

This study is a randomized, simple-blinded comparative phase III clinical trial comparing the immunogenicity of two doses Coronovac to that of a first dose of Coronovac (Sinovac, Beijing, China) followed by a booster shot with the mRNA-based BNT162b2 SARS-CoV-2 vaccine (Comirnaty, Pfizer-BioNTech). The purpose of this study is to evaluate the superiority, safety and immunogenicity of the heterologous prime-boost CoronaVac/BNT162b2 vaccination to the homologous CoronaVac/CoronaVac regimen.

Details

Lead sponsor	Institut Pasteur de Tunis
Phase	PHASE3
Status	COMPLETED
Enrolment	199
Start date	Mon Nov 22 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Sat Jun 25 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• COVID-19

Interventions

• CoronaVac/CoronaVac
• CoronaVac/BNT162b2

Countries

Tunisia